Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib + apatinib maintenance in PARPi-pretreated platinum-sensitive recurrent ovarian cancer
ChiCTR2400085948Phase 4Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jun 2024
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fluzoparib and Rivoceranib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: 6-month progression-free survival rate. Started Jun 2024; status: recruiting.
02
Drugs
fluzoparibRivoceranib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2400085948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085948.